Abstract P2-10-37: Long-term prognosis of early breast cancer in a population-based cohort with a known <i>BRCA1/2</i> mutation status.
MP Nilsson(Lund University), Niklas Loman(Lund University), Åke Borg(Lund University), Håkan Olsson(Nokia (Finland)), Ingrid Idvall(Lund University), Ulf Kristoffersson, Ola Johansson(Reykjavík University), Hartman L Werner(Reykjavík University)
Cited by 0
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
The Life History of 21 Breast Cancers
|Cell|2012|1.5k